Health Care & Life Sciences » Biotechnology | Transgene

Transgene S.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
42,858.00
48,556.00
46,374.00
25,207.00
32,274.00
8,026
Depreciation, Depletion & Amortization
2,911.00
3,039.00
2,636.00
2,267.00
1,691.00
1,733
Other Funds
54,522.00
11,011.00
42,220.00
16,455.00
20,486.00
36,114
Funds from Operations
37,367.00
41,870.00
32,464.00
24,364.00
26,926.00
26,355
Changes in Working Capital
12,818.00
12,366.00
12,688.00
9,221.00
8,444.00
2,026
Net Operating Cash Flow
50,185.00
54,236.00
45,152.00
33,585.00
35,370.00
28,381
Capital Expenditures
2,184.00
2,602.00
1,527.00
47.00
462.00
Sale of Fixed Assets & Businesses
-
-
-
-
100.00
Purchase/Sale of Investments
-
3,134.00
3,843.00
2,020.00
-
Net Investing Cash Flow
4,630.00
532.00
2,316.00
2,067.00
362.00
Issuance/Reduction of Debt, Net
760.00
337.00
117.00
8,597.00
1,234.00
Net Financing Cash Flow
53,832.00
52,061.00
42,580.00
37,222.00
32,524.00
Net Change in Cash
999.00
1,625.00
228.00
1,570.00
3,212.00
Free Cash Flow
52,147.00
56,699.00
46,679.00
33,612.00
35,802.00
Change in Capital Stock
70.00
62,735.00
477.00
45,080.00
13,272.00
Exchange Rate Effect
16.00
18.00
28.00
-
4.00
Other Uses
2,446.00
-
-
-
-

About Transgene

View Profile
Address
400 Boulevard Gonthier dAndernach
Strasbourg Alsace 67405
France
Employees -
Website http://www.transgene.fr
Updated 07/08/2019
Transgene SA is a biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its products include TG4010, Pexa-Vec, TG4001, TG6002, TG1050, and TG4040. The company was founded in December 1979 and is headquartered in Strasbourg, France.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.